Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ed Gane

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
Journal of Viral Hepatitis|May 9, 2020
HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis BLilly Yuen, Peter A Revill, Gillian Rosenberg, et al.
Journal of Hepatology|May 16, 2026
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flaresHeiner Wedemeyer, Ed Gane, Kosh Agarwal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 26, 2023
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug ClassesMarion G Peters, Man-Fung Yuen, Norah Terrault, et al.
The Lancet. Oncology|January 24, 2025
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, studyRichard S Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, et al.
Journal of the International AIDS Society|September 7, 2023
Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT studyJoanne M Carson, Sebastiano Barbieri, Evan Cunningham, et al.
Transplantation Direct|April 20, 2023
The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New ZealandJess Howell, Avik Majumdar, Michael Fink, et al.
Journal of Hepatology|September 3, 2013
Reduction of HBV replication prolongs the early immunological response to IFNα therapyAnthony T Tan, Long Truong Hoang, Daniel Chin, et al.
Gastroenterology|September 20, 2011
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infectionStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Gut|August 19, 2016
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis BJulianne Bayliss, Lilly Yuen, Gillian Rosenberg, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 8, 2021
Turning the Tide on Hepatitis C Virus-Related Liver Transplantation: The Return on Investment in Hepatitis C Virus Treatment in Australia and New ZealandJess Howell, Avik Majumdar, Michael A Fink, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Journal of Viral Hepatitis|May 9, 2020
HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis BLilly Yuen, Peter A Revill, Gillian Rosenberg, et al.
Journal of Hepatology|May 16, 2026
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flaresHeiner Wedemeyer, Ed Gane, Kosh Agarwal, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 26, 2023
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug ClassesMarion G Peters, Man-Fung Yuen, Norah Terrault, et al.
The Lancet. Oncology|January 24, 2025
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, studyRichard S Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, et al.
Journal of the International AIDS Society|September 7, 2023
Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT studyJoanne M Carson, Sebastiano Barbieri, Evan Cunningham, et al.
Transplantation Direct|April 20, 2023
The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New ZealandJess Howell, Avik Majumdar, Michael Fink, et al.
Journal of Hepatology|September 3, 2013
Reduction of HBV replication prolongs the early immunological response to IFNα therapyAnthony T Tan, Long Truong Hoang, Daniel Chin, et al.
Gastroenterology|September 20, 2011
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infectionStefan Zeuzem, Tarik Asselah, Peter Angus, et al.
Gut|August 19, 2016
Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis BJulianne Bayliss, Lilly Yuen, Gillian Rosenberg, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 8, 2021
Turning the Tide on Hepatitis C Virus-Related Liver Transplantation: The Return on Investment in Hepatitis C Virus Treatment in Australia and New ZealandJess Howell, Avik Majumdar, Michael A Fink, et al.
Pageof 8